AMINOSys®, Applied Technology Center, Catalysts - Adsorbent Solutions, Custom Catalysts, Interface & Performance Laboratory, TEGO® Foamex 8880, Lipid Innovation Center, cQrex® AC, Discover Our New Oral Drug Delivery Lab in Istanbul, CDMO for Advanced Drug Delivery, EUDRATEC® SoluFlow, Drawing Drug Delivery: Liposomes, Coatino®, Evonik Delivers First Lipids from German Facility to BioNTech, Hydrogen Peroxide, Polyamide 12, SEPURAN® Green, Specialty Additives
Oral Technologies, CMO for Controlled Substances, Microbial Fermentation, API Contract Manufacturing, Development of High Potency APIs (HPAPIs), Chiral Synthesis, Drug Delivery Technology, Hot Melt Extrusion, Coating Technology
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the speci...
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the specific needs of large or complex projects, they have established a broad portfolio of differentiating technologies. These technologies include catalytic & biocatalytic reactions, large-scale cryogenic chemistry, continuous processing, fermentation, PEGs & mPEGs, catalysts, & polymer APIs.
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the speci...
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the specific needs of large or complex projects, they have established a broad portfolio of differentiating technologies. These technologies include catalytic & biocatalytic reactions, large-scale cryogenic chemistry, continuous processing, fermentation, PEGs & mPEGs, catalysts, & polymer APIs.
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the speci...
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the specific needs of large or complex projects, they have established a broad portfolio of differentiating technologies. These technologies include catalytic & biocatalytic reactions, large-scale cryogenic chemistry, continuous processing, fermentation, PEGs & mPEGs, catalysts, & polymer APIs.
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the speci...
Evonik is one of the world leaders in specialty chemicals.
The company is active in >100 countries around the world & generated sales of €15.3 billion & an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik is one of the world’s largest CDMOs with capabilities to manufacture customized APIs & HPAPIs. To address the specific needs of large or complex projects, they have established a broad portfolio of differentiating technologies. These technologies include catalytic & biocatalytic reactions, large-scale cryogenic chemistry, continuous processing, fermentation, PEGs & mPEGs, catalysts, & polymer APIs.